Heteroaromatic compounds and their use as dopamine D1 ligands

US11964961B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• Michael Aaron Brodney · East Lyme, US
• Jennifer Elizabeth Davoren · Cambridge, US
• Amy Beth Dounay · Colorado Springs, US
• Ivan Viktorovich Efremov · Sharon, US
• David Lawrence Firman Gray · Groton, US
• Michael Eric Green · Boston, US
• Jaclyn Louise Henderson · Cambridge, US
• Chewah Lee · Wallingford, US
• Scot Richard Mente · Arlington, US
• Steven Victor O'Neil · East Lyme, US
• Bruce N. Rogers · Belmont, US
• Lei Zhang · Beijing, CN

Key dates

• Filing date: Mar 17, 2021
• Grant date: Apr 23, 2024
• Expiry date: Jun 16, 2041

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D405/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, bipolar disorder, chronic apathy, anhedonia, chronic fatigue, post-traumatic stress disorder, seasonal affective disorder, social anxiety disorder, post-partum depression, serotonin syndrome, substance abuse and drug dependence, drug abuse relapse, Tourette's syndrome, tardive dyskinesia, drowsiness, excessive daytime sleepiness, cachexia, inattention, sexual dysfunction, migraine, SLE, hyperglycemia, atherosclerosis, dislipidemia, obesity, diabetes, sepsis, post-ischemic tubular necrosis, …